Concerning the Doliprane sale file, the French government announced, on Sunday October 20, the signing of a “ tripartite agreement » between the State, Sanofi and the American investment fund CD&R, which recovers 50% of the shares of Opella, the laboratory which produces the favorite drug of the French. The State will also enter the capital, via the investment of Bpifrance.
2 mins
After a week of negotiations, the French State obtained several commitments from Sanofi and its buyer. The active products in Opella’s medicines will be produced domestically, and the French market will remain a priority.
Another important gain: CD&R is committed to growing the subsidiary it buys. This investment promise has not yet been quantified, but the office of the Minister ofIndustry speaks of a precious guarantee which secures progress on the industrial level, particularly in terms of employment.
The Ministries of Economy and Industry are pleased to have obtained an agreement “ up to what they asked for “. “ We have reached the highest level of guarantees possible in the discussions » with Sanofi on this issue, specified the offices of the Ministers of Economy and Industry.
This ” tripartite agreement » goes in the direction of health and industrial sovereignty, assures the entourage of the Minister ofEconomy. The French Minister of the Economy, Antoine Armand, assured on obtained guarantees of maintenance and development in France » of this subsidiary which represents 1,700 jobs in France and about which the unions are worried. “ Our demands on employment, production and investment will be respected. For Doliprane and other essential medicines in the country “, he added.
Also readThe announced sale of Doliprane by Sanofi raises many fears
In addition to this agreement, the government obtained an entry into the capital of Bpifrance, the public investment bank, which will allow the State to sit on the board of directors and monitor the evolution of the company from the inside. the subsidiary.
Behind assurance for the government, since it is a sensitive sector: the transaction will be subject to a foreign investment procedure in France. A control which will allow the Minister of the Economy to review the file in depth before approving, or not, the acquisition.
Also readDoliprane: the French executive tries to calm concerns